Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
May 04, 2023 16:05 ET
|
Assembly Biosciences, Inc.
Herpesvirus candidate ABI-5366 progressing towards IND and planned to enter the clinic in the first half of 2024Additional development candidate nomination anticipated in 2023Multiple abstracts...
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
April 18, 2023 08:00 ET
|
Assembly Biosciences, Inc.
Phase 1a clinical data for remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication and...
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
March 22, 2023 16:05 ET
|
Assembly Biosciences, Inc.
Prioritization of core inhibitor candidate ABI-4334 and pausing of core inhibitor candidate ABI-H3733 based on data to date from ongoing clinical Phase 1 studies of both candidates and chronic...
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
February 15, 2023 08:00 ET
|
Assembly Biosciences, Inc.
−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN...
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
December 19, 2022 08:00 ET
|
Assembly Biosciences, Inc.
In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction...
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
November 14, 2022 08:00 ET
|
Assembly Biosciences, Inc.
Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB),...
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
November 08, 2022 16:05 ET
|
Assembly Biosciences, Inc.
Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Assembly...
Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor
July 20, 2022 16:10 ET
|
Arbutus Biopharma Corporation
Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences’ core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022 ...
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
February 26, 2021 07:30 ET
|
Arbutus Biopharma Corporation; Assembly Biosciences, Inc.
Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER,...
Assembly Biosciences Announces Key Additions to Microbiome Team
September 28, 2016 07:00 ET
|
Assembly Biosciences
INDIANAPOLIS, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing novel oral therapeutics for disorders associated with the human...